Alveolar Echinococcosis: Parasite Viability and Innovative Markers for the Follow-up of Patients Treated With Albendazole

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study design to define improved management of patients with hepatic alveolar echinococcosis treated with albendazole and especially make appropriate and timely decision of treatment withdrawal .

Based on exploratory analysis of existing and newly developed biological and imaging exams, for diagnosis and follow-up, and study of the relationship of these markers to the viability of the parasite and/or the activity of the parasitic lesions The study included two series of patients: operated on (curative hepatectomy) // non-operated on

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis

NCT05824442

Echinococcosis Diagnosis

RECRUITING NA

Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)

NCT02947581

Neurocysticercosis

TERMINATED PHASE3

Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France

NCT04810741

Schistosomiasis

COMPLETED

Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection

NCT00001645

Malaria Intestinal Worms GI Protozoa +2 more

RECRUITING

RCT ALB for SA Cysticercosis

NCT00133458

Subarachnoid Cysticercosis

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Close follow-up of the patients, based on WHO guidelines (Brunetti, Acta tropica 2010), including albendazole bloods levels determination.

Clinical exam, sampling and storing (biobank) of blood specimens at inclusion, M1, M3, M6, M9, M12, M18, M24, M30, M36, M44, M48.

Additional sampling for operated on patients : M15 and M21.

Imaging each year (US, CT, PET-CT \& RMI).

Preservation of operative specimens samples at -80°C: samples taken at different location (center and periphery of the lesions) and in distant non-infected liver, for further studies of the immune response, RNA detection, and albendazole dosages.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alveolar Echinococcosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hepatic alveolar echinococcosis

Follow-up of standardized clinical, biological, and imaging characteristics (according to the WHO-expert consensus). Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)

Standardized earlier withdrawal of benzimidazole :

* Patients with non operable hepatic AE lesion : Withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after at least 4 years when viability markers became negative (PET-CT, serological markers)
* Curative hepatectomy : Earlier withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after one year (WHO guidelines : 2 years), if viability markers became negative. Close prospective follow-up after withdrawal (PET-CT, serological markers)

Group Type OTHER

Benzimidazole

Intervention Type DRUG

Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Benzimidazole

Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Standardized earlier withdrawal of albendazole

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hepatic alveolar echinococcosis
* without antiparasitic treatment or with antiparasitic treatment and hepatectomy programmed

Exclusion Criteria

* Patients with exclusively extra-hepatic form of alveolar echinococcosis
* Women without effective contraception (Contraindication to benzimidazoles)
* The immunosuppressed patients or receiving an immunosuppressive treatment will not be the object of a stop of the post-operative treatment by albendazole on 1 year after the intervention of radical resection; they can be included in the study but will receive the albendazole during 2 years; this exclusion applies to the patients treated by liver transplant.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No